Herb induced liver injury presumably caused by black cohosh: A survey of initially purported cases and herbal quality specifications
| Autor: | Alexander Schwarzenboeck, Albrecht Wolff, Wolfgang Schmidt-Taenzer, Karl-Heinz Hennermann, Rolf Teschke |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Cimicifuga
food.ingredient media_common.quotation_subject Black cohosh Specialties of internal medicine Herb induced liver injury food Environmental health Black cohosh induced liver injury Prevalence Adverse Drug Reaction Reporting Systems Humans Medicine Actaea cimicifuga Quality (business) Quality of Health Care media_common Hepatology Traditional medicine Plant Extracts business.industry Hepatotoxicity General Medicine Health Surveys Causality RC581-951 Herb Herbal hepatotoxicity Female Naranjo Scale Drug induced liver injury Chemical and Drug Induced Liver Injury Menopause business Phytotherapy |
| Zdroj: | Annals of Hepatology, Vol 10, Iss 3, Pp 249-259 (2011) |
| ISSN: | 1665-2681 |
| Popis: | Herb induced liver injury (HILI) is a particular challenge that also applies to purported cases presumably caused by black cohosh (BC), an herb commonly used to treat menopausal symptoms. We analyzed and reviewed all published case reports and spontaneous reports of initially alleged BC hepatotoxicity regarding quality of case details and causality assessments. Shortcomings of data quality were more evident in spontaneous reports of regulatory agencies compared to published case reports, but assessments with the scale of CIOMS (Council for the International Organizations of Sciences) or its updated version revealed lack of causality for BC in all cases. The applied causality methods are structured, quantitative, and liver specific with clear preference over an ad hoc causality method or the liver unspecific Naranjo scale. Reviewing the case data and the reports dealing with quality specifications of herbal BC products, there is general lack of analysis with respect to authentication of BC in the BC products used by the patients. However, in one single regulatory study, there was a problem of BC authentication in the analysed BC products, and other reports addressed the question of impurities and adulterants in a few BC products. It is concluded that the use of BC may not exert an overt hepatotoxicity risk, but quality problems in a few BC products were evident that require additional regulatory quality specifications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|